Opening Paragraph (User Pain Point & Solution Direction): Neurologists, headache specialists, and primary care physicians managing patients with chronic migraines (defined as ≥15 headache days per month, with ≥8 meeting migraine criteria, lasting ≥3 months) face a critical therapeutic challenge: patients with high-frequency episodic migraine (4-14 headache days/month) or chronic migraine require preventive (prophylactic) treatment to reduce attack frequency, duration, and severity, improve migraine-related disability, enhance quality of life, reduce associated psychological disorders (anxiety, depression), improve acute treatment response rates, and reduce dependence on acute medications (triptans, NSAIDs, ergots) to avoid medication-overuse headache (MOH). Preventive treatment aims to reduce the frequency, duration, and severity of migraine attacks, improve migraine-related disability, improve quality of life, reduce related psychological disorders caused by frequent or chronic headaches, improve the response rate to acute treatment, reduce dependence on acute treatment, and avoid the occurrence of drug overuse headache. The proven solution lies in a range of preventive migraine therapies: traditional oral prophylactics (beta-blockers (propranolol, metoprolol, timolol), anti-epileptic drugs (topiramate, valproate), calcium channel blockers (verapamil, flunarizine), antidepressants (amitriptyline, venlafaxine)), and newer biologic CGRP (calcitonin gene-related peptide) pathway-targeting monoclonal antibodies (erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), eptinezumab (Vyepti)). This market research deep-dive analyzes the global preventive treatment of migraines market size, market share by drug class (calcium channel blockers, anti-epileptic drugs, beta-blockers, calcium channel modulators, antidepressants, and other (including CGRP mAbs, gepants (rimegepant, ubrogepant) for prevention, onabotulinumtoxinA (Botox))), and application-specific demand drivers across hospitals (neurology inpatient/outpatient, headache clinics), and other settings (specialty pharmacies, mail-order, retail pharmacies). Based on historical data (2021-2025) and forecast calculations (2026-2032), the report delivers actionable intelligence for pharmaceutical product managers, neurologists, formulary decision-makers, and healthcare procurement specialists. Global Leading Market Research Publisher QYResearch announces the release of its latest report "Preventive Treatment of Migraines - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Preventive Treatment of Migraines market, including market size, share, demand, industry development status, and forecasts for the next few years. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5973330/preventive-treatment-of-migraines Market Size & Growth Trajectory (Updated with Recent Data): The global market for preventive treatment of migraines was estimated to be worth US7.5billionin2025andisprojectedtoreachUS 11.8 billion by 2032, growing at a CAGR of 6.7% from 2026 to 2032. This robust growth (6.7% CAGR, outpacing overall pharmaceutical market at 5%) is driven by three primary forces: (1) launch and rapid uptake of CGRP monoclonal antibodies (erenumab (2018), galcanezumab (2018), fremanezumab (2018), eptinezumab (2020))—first preventive migraine therapies specifically designed for migraine prophylaxis (previous drugs were repurposed antihypertensives, anticonvulsants, antidepressants); (2) increasing prevalence of migraine (global prevalence estimated at 1.04 billion people (14-15% of world population), with higher rates in females (18-20% vs. males 6-8%), and chronic migraine (2-3% of population)); (3) expanded indications and novel formulations—CGRP mAbs approved for both episodic and chronic migraine; oral CGRP receptor antagonists (gepants) approved for acute and prevention (rimegepant (Nurtec ODT) approved for prevention 2021, atogepant (Qulipta) approved 2021 for episodic migraine prevention); FDA approval of eptinezumab intravenous infusion (Vyepti) for prevention (fast-acting, quarterly administration). The broader pharmaceutical market context: the global pharmaceutical market was valued at 1,475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs (small molecules) and biological drugs (biologics). Biologics market was estimated at 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1,005 billion USD in 2018 to 1,094 billion USD in 2022. Pharmaceutical market factors include increasing demand for healthcare, technological advancements, rising prevalence of chronic diseases (including migraine), increased funding from private & government organizations for pharmaceutical manufacturing, and rising R&D activities for drugs. However, the industry also faces challenges: stringent regulations (FDA, EMA), high R&D costs ($1-2 billion per new chemical entity), and patent expirations. Companies must continuously innovate and adapt to remain competitive. The COVID-19 pandemic highlighted the importance of vaccine development and supply chain management, emphasizing the need for pharmaceutical companies to be agile and responsive. Notably, Q1 2026 industry data indicates a 30% YoY rise in CGRP mAb prescriptions (particularly galcanezumab (Emgality) and fremanezumab (Ajovy)) for chronic migraine prevention following positive real-world evidence studies and expanded insurance coverage (prior authorization requirements reduced). North America accounted for 55% of global demand in 2025 (highest CGRP mAb adoption rates, favorable reimbursement), followed by Europe (25%) and Asia-Pacific (12%), with Asia-Pacific expected to grow at the fastest CAGR (8.0%) driven by increasing diagnosis rates, CGRP mAb approvals (Japan, China, South Korea, Australia), and expanding healthcare access. Technical Deep-Dive: Drug Class Mechanisms, Efficacy, and Safety Profiles: Traditional Oral Preventive Migraine Medications (Repurposed from Other Indications): Drug Class Examples Mechanism Efficacy (Migraine Days/Month Reduction) Common Side Effects Use Limitations Market Share (value, 2025) Cost (US$/month) Beta-Blockers Propranolol, metoprolol, timolol Beta-1 and beta-2 adrenergic receptor antagonism; mechanism in migraine unknown (possibly vascular, neural) 30-50% responder rate (≥50% reduction in migraine days) Fatigue, bradycardia, hypotension, depression, sexual dysfunction Contraindicated in asthma, heart block ~15% $10-50 Anti-Epileptic Drugs (AEDs) Topiramate (Topamax), valproate/divalproex (Depakote) Multiple: GABA potentiation (valproate), sodium/calcium channel blockade, AMPA/kainate antagonism (topiramate) Topiramate: 30-50% responder rate; valproate: 30-40% Topiramate: cognitive dysfunction (word-finding difficulty, memory loss), paresthesias, weight loss; valproate: weight gain, tremor, teratogenicity Topiramate: cognitive side effects limit use; valproate: teratogenic (avoid in women of childbearing potential) ~20% $20-100 Calcium Channel Blockers Verapamil, flunarizine (not FDA approved in US) L-type calcium channel blockade 20-40% responder rate Constipation (verapamil), weight gain, sedation (flunarizine) Limited efficacy; not first-line ~5% $10-40 Antidepressants Amitriptyline (tricyclic), venlafaxine (SNRI) Amitriptyline: serotonin/norepinephrine reuptake inhibition (weak); venlafaxine: SNRI Amitriptyline: 30-40% responder rate; venlafaxine: 20-30% Amitriptyline: sedation, dry mouth, weight gain, constipation, cardiotoxicity (overdose); venlafaxine: nausea, insomnia, sexual dysfunction Amitriptyline: side effect burden; venlafaxine: limited evidence ~10% $5-50 Other (ACE inhibitors, ARBs, NSAIDs, etc.) Lisinopril, candesartan, naproxen Various Limited evidence; not first-line Variable Not guideline-recommended as first-line ~5% $5-30 CGRP Pathway-Targeting Therapies (Biologics & Small Molecules)—Revolutionized Migraine Prevention: Drug Class Examples Mechanism Efficacy (Migraine Days/Month Reduction) Common Side Effects Advantages Market Share (value, 2025) Cost (US$/month) CGRP Monoclonal Antibodies (mAbs) Erenumab (Aimovig)—Amgen/Novartis; Galcanezumab (Emgality)—Lilly; Fremanezumab (Ajovy)—Teva; Eptinezumab (Vyepti)—Lundbeck Erenumab: CGRP receptor antagonist; others: CGRP ligand antibodies 50-60% responder rate; 3-5 migraine days reduction/month; onset 1-3 months Injection site reactions (pain, redness), constipation (erenumab), fatigue Monthly subcutaneous (erenumab/galcanezumab/fremanezumab) or quarterly IV (eptinezumab); specifically developed for migraine prevention ~35% (fastest growing) $600-700 (before insurance/rebates) Oral CGRP Receptor Antagonists (Gepants) for Prevention Rimegepant (Nurtec ODT)—Biohaven (Pfizer); Atogepant (Qulipta)—AbbVie Small molecule CGRP receptor antagonists (competitive inhibition) Rimegepant (prevention): 2.5-3.5 days reduction; atogepant: 3-4 days reduction Nausea, abdominal pain, dyspepsia (mild) Oral (daily atogepant, every-other-day rimegepant); also approved for acute treatment (rimegepant) ~15% $600-800 (before insurance) OnabotulinumtoxinA (Botox) Allergan (AbbVie) Blocks acetylcholine release from presynaptic nerve terminals at neuromuscular junction; mechanism in migraine: inhibition of CGRP and substance P release from trigeminal nerve endings 50-60% responder rate (chronic migraine specifically); 7-10 days reduction/month Neck pain, muscle weakness, injection site pain; transient Specifically approved for chronic migraine (≥15 headache days/month); quarterly administration (31-39 injection sites, 155-195 units) ~15% $1,000-1,500 per session (every 12 weeks) Key Clinical Insights: Preventive treatment initiation: Consider for patients with ≥4 migraine days/month, significant disability (MIDAS score ≥11, HIT-6 score ≥56), or failure of acute treatments, medication overuse headache, or presence of rare migraine variants (hemiplegic migraine, basilar migraine, migraine with brainstem aura). First-line preventive (traditional): Beta-blockers, topiramate, amitriptyline (low cost, established efficacy, but side effect burden). Preferred for episodic migraine. First-line preventive (specialty): CGRP mAbs (high efficacy, low side effect burden, but high cost). Preferred for chronic migraine, patients who have failed or cannot tolerate traditional preventives, or have contraindications. OnabotulinumtoxinA: Specifically for chronic migraine (≥15 headache days/month). Not approved for episodic migraine. Oral gepants (rimegepant, atogepant): Newest class; offer oral administration (vs. injection for mAbs) and dual acute+prevention use (rimegepant). Industry Segmentation: Drug Class—CGRP mAbs Fastest Growing, Traditional Orals Still Volume Leaders CGRP Monoclonal Antibodies (~35% Market Share, 20% CAGR) —fastest-growing segment driven by launch of multiple mAbs, expanded indications (episodic + chronic migraine), and real-world evidence. Key players: Eli Lilly (Emgality), AbbVie (Botox; Qulipta), Pfizer/Biohaven (Nurtec ODT), Amgen/Novartis (Aimovig), Teva (Ajovy), Lundbeck (Vyepti). Higher cost ($600-700/month before insurance) but increasingly covered by commercial insurance and Medicare Part D (with prior authorization). Oral CGRP Antagonists (Gepants) for Prevention (~15% Market Share, 25% CAGR) —rimegepant (Nurtec ODT) and atogepant (Qulipta) approved 2021. Dual use (acute + prevention) for rimegepant simplifies prescribing. Oral administration preferred by some patients over injectable mAbs. OnabotulinumtoxinA (~15% Market Share, Stable) —established for chronic migraine since 2010 (PREEMPT trials). Generic erosion limited (biologic, but biosimilars in development). Quarterly administration, requires specialist administration (neurologist, headache specialist, or trained nurse). Traditional Orals (Beta-Blockers, AEDs, Antidepressants, CCBs) (~35% Market Share, Declining Slightly) —still largest volume (prescriptions), but value declining due to generic pricing ($5-100/month) and shift to higher-priced biologics. Segment by Type (Drug Class): Calcium Channel Blockers (verapamil, flunarizine; $10-40/month) Anti-Epileptic Drugs (topiramate, valproate; $20-100/month) Beta-Blockers (propranolol, metoprolol, timolol; $10-50/month) Calcium Channel Modulators (atogepant, rimegepant; $600-800/month) Antidepressants (amitriptyline, venlafaxine; $5-50/month) Other (CGRP mAbs (erenumab, galcanezumab, fremanezumab, eptinezumab), onabotulinumtoxinA ($1,000-1,500/quarter), gepants (already covered)) Segment by Application (Distribution Channel): Hospital (~30% of demand)—neurology inpatient consultation for status migrainosus, refractory migraine requiring inpatient treatment; onabotulinumtoxinA administration in hospital-based headache clinics/infusion centers (eptinezumab IV, Botox injections, CGRP mAb loading doses?). Clinic (~60% of demand, largest segment)—outpatient neurology, headache specialty clinics, primary care (initiating traditional oral preventives); CGRP mAbs prescribed by neurologists, dispensed via specialty pharmacy (mail-order) or retail pharmacy; Botox injections performed in clinic. Other (~10% of demand)—specialty pharmacies (mail-order for CGRP mAbs and oral gepants), long-term care facilities, home health (CGRP mAb self-injection training). Recent Policy & Technical Challenges (2025-2026 Update): In November 2025, the U.S. FDA approved the first interchangeable biosimilar to onabotulinumtoxinA (Botulax, Evolus) for chronic migraine, potentially reducing cost and expanding access (expected launch 2026-2027). Meanwhile, a key challenge persists: high cost and prior authorization burden for CGRP mAbs (600−700/monthlistprice,patientout−of−pocket0-100 with insurance, $600-700 without). Many insurers require failure of ≥2 traditional oral preventives before authorizing CGRP mAbs. Some states have enacted step-therapy reform laws limiting fail-first requirements. Additionally, a December 2025 update to the American Headache Society (AHS) consensus guidelines added rimegepant and atogepant as first-line preventive options for episodic migraine (along with beta-blockers, topiramate, amitriptyline), recognizing high efficacy and favorable tolerability. The guidelines also recommended CGRP mAbs as first-line for chronic migraine (along with onabotulinumtoxinA). Real-world evidence studies (2024-2026) confirmed CGRP mAbs reduce migraine days by 50-70% in clinical practice (similar to RCTs), with persistence >12 months in 60-70% of patients. The global pharmaceutical market factors such as increasing demand for healthcare, technological advancements, rising prevalence of chronic diseases, increased funding for R&D, and regulatory harmonization continue to drive market growth. Selected Industry Case Study (Exclusive Insight): A US headache specialty clinic (field data from February 2026) retrospectively analyzed outcomes of 350 chronic migraine patients (≥15 headache days/month) who initiated galcanezumab (Emgality) preventive therapy (loading dose 240mg (two 120mg injections), then 120mg monthly). Over a 12-month treatment period, the clinic documented three measurable outcomes: (1) median monthly migraine days reduced from 18 days to 6 days (67% reduction), (2) responder rate (≥50% reduction) = 68%, (3) discontinuation rate = 14% (most due to lack of efficacy, not side effects). Prior failure of ≥3 traditional oral preventives (beta-blockers, topiramate, amitriptyline) was common. Patient satisfaction (PGIC) rated "much improved" or "very much improved" in 72%. The clinic now recommends CGRP mAbs as first-line preventive for chronic migraine patients with prior oral preventive failures. Competitive Landscape & Market Share (2025 Data): The Preventive Treatment of Migraines market is concentrated among pharmaceutical companies with CGRP mAbs and oral gepants: Eli Lilly and Co. (USA): ~18% (galcanezumab (Emgality)—CGRP mAb) AbbVie Inc. (USA): ~15% (onabotulinumtoxinA (Botox), atogepant (Qulipta)) Biohaven (Pfizer) (USA): ~12% (rimegepant (Nurtec ODT)) Teva Pharmaceutical Industries (Israel): ~8% (fremanezumab (Ajovy)) Amgen/Novartis (USA/Switzerland): ~8% (erenumab (Aimovig)) Lundbeck (Denmark): ~5% (eptinezumab (Vyepti)) Traditional oral generics manufacturers (multiple, not listed individually) —Cipla, Torrent, Aa Pharma, Karnataka Antibiotics, Cadila, Orchid, Fdc, Alkem, Intas: ~20% combined (low value/high volume) Others (smaller generic manufacturers, emerging biosimilars): ~14% Note: Traditional oral preventives (beta-blockers, AEDs, antidepressants, CCBs) are generic, low-cost, manufactured by many companies (including Cipla, Torrent, Aa Pharma, Karnataka Antibiotics, Cadila, Orchid, Fdc, Alkem, Intas). CGRP mAbs and oral gepants are branded, high-cost, manufactured by fewer companies. Exclusive Analyst Outlook (2026–2032): Our analysis identifies three under-monitored growth levers: (1) generic CGRP mAbs and biosimilars—first patents for erenumab expire 2031-2033 (early patent expiration for galcanezumab 2027-2028?), biosimilars could reduce cost 30-50%, expanding access, but expected late-decade (2028-2032); (2) oral CGRP antagonists (gepants) for prevention—rimegepant and atogepant currently have 2025-2027 patent protection; triple-indication (acute, episodic prevention, chronic prevention) possible for rimegepant; additional gepants in development; (3) novel mechanisms—CGRP ligand trap, PACAP (pituitary adenylate cyclase-activating peptide) antagonists, serotonin 5-HT1F agonists (lasmiditan) for acute, but not yet approved for prevention; pipeline agents may enter market 2028-2030. Conclusion & Strategic Recommendation: Neurologists and headache specialists should select preventive migraine treatment based on attack frequency (episodic vs. chronic), prior treatment response, comorbidities, and patient preference. For episodic migraine (4-14 days/month), first-line options include traditional orals (beta-blockers, topiramate, amitriptyline), oral gepants (rimegepant or atogepant), or CGRP mAbs (especially for patients with contraindications or side effects to oral preventives). For chronic migraine (≥15 days/month), first-line options include CGRP mAbs or onabotulinumtoxinA (head-to-head trials show similar efficacy, choice depends on tolerability, cost, and administration preference (monthly self-injection vs. quarterly in-office injection)). CGRP mAbs are generally better tolerated (fewer systemic side effects) but more expensive. For patients with medication overuse headache (MOH), preventive treatment (CGRP mAb studies show MOH resolution) should be initiated while withdrawing acute medications. For patients with prior failure of 2+ oral preventives, guidelines recommend CGRP mAbs or onabotulinumtoxinA. Prior authorization may be required; patient assistance programs available for uninsured/underinsured. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp